NovaBridge Biosciences announced its annual general meeting (AGM) will be held on September 8, 2026, in Shanghai. The company is advancing clinical-stage biopharmaceutical treatments, including givastomig for gastric cancer and VIS-101 for retinal diseases. These developments are significant as they target unmet medical needs with innovative therapies currently in Phase 2 trials. The AGM will also review the company's 2025 financial report and strategic plans moving forward.
Pelthos Therapeutics announced its 2026 Annual Meeting of Stockholders will be held virtually on September 29, 2026, at 9:00 a.m. Eastern Time. Stockholders of record as of August 4, 2026, are eligible to vote. The company will file the official noti...
Mdxhealth announced it received a Nasdaq notification for failing to meet the minimum market value of listed securities requirement of $35 million. The company has 180 days, until January 19, 2027, to regain compliance by exceeding this market value ...
AMREP Corporation announced a net income of $10.3 million, or $1.91 per diluted share, for its fiscal year ending April 30, 2026, down from $12.7 million, or $2.37 per diluted share, in the previous year. Despite the drop in net income, revenues incr...
Dassault Aviation reported higher earnings and sales in the first half of 2026, prompting Jefferies to raise its price target from EUR 410 to EUR 420 and maintain a Buy rating. The stock rose over 8% following the positive financial results. However,...
Volkswagen AG reported Q2 earnings per share of $0.30, missing analyst estimates of $0.60, with operating profit down nearly 10% to €3.5 billion due to market challenges including lower demand in China and U.S. tariffs. However, revenue rose to $93.7...
